Home example 2 - Pharmamarketeer

wet- en regelgeving

RNAi Therapy Gets Breakthrough Status for Primary Hyperoxaluria Type 1

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DCR-PHXC (Dicerna Pharmaceuticals) for the treatment of patients with primary hyperoxaluria type 1 (caused by a mutation in the AGXT...

Monthly Prescribing Reference (MPR): Drugs in the Pipeline

3 x gelezen

farma-industrie

HSS Secretary Alex Azar responds to pharma sector’s criticism over Medicare pricing plan

US Health and Human Services (HHS) Secretary Alex Azar responded to industry criticism on Friday after big pharma warned that Trump’s initiative, aimed at lowering the prices Medicare pays for drugs, would see the...

InPharm.com

3 x gelezen

onderzoek

AstraZeneca & Merck receive $1 billion boost from cancer drug success

AstraZeneca’s oncology business received a boost as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line...

Reuters Health

3 x gelezen

marketing

Efficiency en disruptie

Op Marketingfacts delen NIMA Register Marketeers hun mening over vakliteratuur. Welke boeken zijn interessant of relevant en wat vinden ervaren marketingprofessionals ervan? We recenseren de meest uiteenlopende...

Marketingfacts.nl

3 x gelezen

wet- en regelgeving

Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer

Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by Roche and Genentech’s Herceptin (trastuzumab) with the announcement that their own biosimilar version of...

InPharm.com

3 x gelezen

farma-industrie onderzoek

GSK and Sanofi join Finland’s 500,000 genomics study

GlaxoSmithKline and Sanofi have joined academic groups and other pharma companies to take part in Finland’s large scale genomics project, based on data from 500,000 biobank volunteers.

PMLiVE

3 x gelezen

overig

Biogen boosts investment in neurology with $1 billion Ionis deal

U.S. drugmaker Biogen rolled out part of its $37 billion investment warchest on Friday, signing a $1 billion deal that seeks to expand on the strength of an existing partnership with Ionis Pharmaceuticals Inc.

Reuters

3 x gelezen

wet- en regelgeving

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 years old. AbbVie’s two drug combo tablets have been approved as a treatment for all...

InPharm.com

3 x gelezen

marketing

Contentmarketing is geen vakgebied, maar een mindset

We draaien rondjes. Wat is nou precies contentmarketing? Ik kan je verklappen: alles, zolang je de consument op de eerste plek zet.

Adformatie Nieuws

3 x gelezen

onderzoek

GSK’s ovarian cancer treatment meets main goal in late-stage study

GlaxoSmithKline said on Monday a late-stage study testing its initial maintenance therapy, Zejula, in patients with ovarian cancer who have undergone platinum-based chemotherapy showed positive results.

Reuters Health

3 x gelezen

Latest articles

RNAi Therapy Gets Breakthrough Status for Primary Hyperoxaluria Type 1

HSS Secretary Alex Azar responds to pharma sector’s criticism over Medicare pricing plan

AstraZeneca & Merck receive $1 billion boost from cancer drug success

Efficiency en disruptie

Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer

GSK and Sanofi join Finland’s 500,000 genomics study

Biogen boosts investment in neurology with $1 billion Ionis deal

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

Contentmarketing is geen vakgebied, maar een mindset

GSK’s ovarian cancer treatment meets main goal in late-stage study

Wekelijkse highlights per e-mail

Algemene informatie